Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.

[1]  E. Perez.  Current management of metastatic breast cancer. , 1999, Seminars in oncology.

[2]  M. Marty,et al.  Optimizing Chemotherapy for Patients with Advanced Breast Cancer , 1999, Oncology.

[3]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Hortobagyi,et al.  Treatment of breast cancer. , 1998, The New England journal of medicine.

[5]  E. Winer,et al.  Oral 5-FU analogues in the treatment of breast cancer. , 1998, Oncology.

[6]  V Torri,et al.  Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[8]  A. Harris,et al.  Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. , 1998, British Journal of Cancer.

[9]  H. Ishitsuka,et al.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. , 1998, Biochemical pharmacology.

[10]  J. Hainsworth.  Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel. , 1997, European journal of cancer care.

[11]  D M Parkin,et al.  Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. , 1997, European journal of cancer.

[12]  S. Payne.  A study of quality of life in cancer patients receiving palliative chemotherapy. , 1992, Social science & medicine.

[13]  M. Nooij,et al.  "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). , 1991, European journal of cancer.

[14]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.

[15]  C. Mathelin,et al.  [Breast cancer: epidemiology, risk factors, screening]. , 1998, La Revue du praticien.

[16]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.